Insulet names Mazelsky to board
By HME News Staff
Updated 11:00 AM CDT, Thu June 25, 2026
ACTON, Mass. – Insulet has appointed Jonathan “Jay” Mazelsky to its board of directors, effective July 1. Mazelsky joins the board as an independent director and currently serves as executive chair of the board of directors of IDEXX Laboratories, a provider of animal health diagnostics and software. “Insulet has built a strong category-leading business based on Omnipod’s unique AID system, clinical evidence and real-world outcomes, and I am truly inspired by the company’s relentless commitment to reduce the burden of diabetes,” said Mazelsky. “I look forward to working with Ashley, the board, and the executive leadership team as Insulet continues to build on its momentum and deliver stakeholder value.” During his 14-year tenure as an executive at IDEXX, Mazelsky served as president and CEO from October 2019 to May 2026, interim president and CEO from June 2019 to October 2019, and executive vice president from August 2012 to June 2019, responsible for the company’s North American Companion Animal Group Commercial Organization, as well as key elements of its innovation portfolio. Before joining IDEXX, Mazelsky held leadership roles at Philips Healthcare, Agilent Technologies and Hewlett Packard. “Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value,” said Ashley McEvoy, president and CEO of Insulet. “His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leadership position.”
Comments